Welcome to our new website! Please reset your password before logging in. Need help? Contact us: customer.service@sfihealth.com

Quick Links
cart icon 0
Close-up background of ivy leaves.
sfi health news and blog icon Chesty Cough

Ivy Leaf Extract

Hedera helix EA 575

Extensive research and careful processing methods mean that both adults and children can benefit from a reliable cough remedy made from ivy leaves.

Jump To:

The Ingredients

Preparations from Ivy leaf, or Hedera helix as it is known botanically, are well established for the relief of productive or chesty coughs.

In the SFI Health Prospan range, a specific extract from the leaves of Hedera helix is used, called EA 575®. This extract is carefully obtained through a patented extraction process that helps ensure a consistent composition of ingredients. This is critical because it’s this specific extract EA 575 that’s been the subject of extensive clinical research ­– showing triple action chesty cough relief in thousands of patients, both children and adults.1-8

Discover more about the exclusive EA 575 extract used in SFI Health Prospan.

EA 575® in Prospan: Clinical studies

EA 575® has been investigated in numerous research publications, including clinical trials and observational studies, involving more than 65,000 patients.1

LANG ET AL., 2015 2

1066 school children (aged 6-12) studied over 1 week
IMPROVEMENT

of cough, expectoration, breathing symptoms due to a cold.

  • Additionally: improvement in symptoms was demonstrated after as little as 3.48 days

*Study included Prospan, Prospan Drops and Prospan lozenges.*

FAZIO ET AL., 2009 3

9657 patients (aged 0-98 years*) studied over 7 days
IMPROVEMENT
  • Cough (93% of patients)
  • Clearance of chest mucus due to a cold (93% of patients)
  • Breathing symptoms due to a cold (91% of patients)
  • Good or very good tolerability (97% of patients)

Study included Prospan.*

SCHAEFER ET AL., 2016 4

181 adults with acute cough (aged 18-75 years) studied over 7 days
SIGNIFICANT IMPROVEMENT

vs. placebo for:

  • Cough severity over period of 7 days
  • Relief within 48 hours

Study included Prospan Menthol.*

BOLBOT ET AL., 2003 6

50 children (2-10 years of age) studied over 7-10 days
SIGNIFICANT IMPROVEMENT
  • Breathing symptoms due to a cold

*Additionally : 96% of patients rated efficacy of Prospan ‘good’ or ‘very good’ and tolerability of Prospan rated as ‘good’ or ‘very good’ in 100% of patients

Study included Prospan.*

 

KRAFT ET AL., 2004 6

52,478 children (up to 12 years of age)
RETROSPECTIVE SURVEY CONFIRMATION
  • very good tolerability in a large group of patients

Study included Prospan.*

MAIDANNIK ET AL., 2003 7

72 patients (up to 15 years of age) studied over 7-14 days
POSITIVE RESULTS
  • Patients rated symptom reduction and efficacy as excellent of good in 87% of cases

Study included Prospan.*

MEYER-WEGENER ET AL., 1993 8

99 patients (aged 25-70) studied over 4 weeks
IMPROVEMENT
  • Breathing symptoms due to a cold

Study included Prospan Drops.*

*Prospan and Prospan for Children are not to be used in children under 2 years without medical advice. Prospan Menthol and lozenges are not to be given to children under 6 years. Prospan Drops are not to be given to children under 12 years. These medicines may not be right for you. Read the warnings before purchase. These can be found in the dosage sections of the Prospan product web pages. Follow the directions for use. If symptoms or coughing persist, talk to your health professional.

SFI Health Difference

EA 575 vs. Hedera helix – The Prospan difference

Natural healthcare products can vary considerably depending on how they are produced. The specific EA 575 extract used in the Prospan range is produced using a rigorous and controlled process with careful consideration at every stage of creation.

This helps to ensure the Prospan with EA 575  you are getting is high quality with a consistent amount and composition of active ingredient, consistently reliable, and the same as the medicine researched in clinical studies to deliver chesty cough relief.1

Prospan with EA 575: A Summary

Consistent quality

Rigorous processes, quality controls and extensive testing ensures that Prospan with  EA 575 can provide the desired health outcomes demonstrated in clinical studies.1

Over 65 years of research & development

Investigating the beneficial effect of Prospan with EA 575 in patients with chesty cough.1

20 research publications

Support the role of Prospan with EA 575 in relieving the symptoms of a chesty cough.3

World's No.1 natural chesty cough medicine

Recommended and used by millions of people worldwide for reliable chesty cough relief. 13

Available Resources

Educational Articles Restricted A Pharmacists Perspective - Treating Chesty Cough in Children Under Two Years of Age- the Clinically Proven Option

A Pharmacists Perspective – Treating Chesty Cough in Children Under Two Years of Age- the Clinically Proven Option

The latest directives from the TGA herald significant adjustments in our approach to aiding parents grappling with cough-related challenges in infants under two. While product labels offer guidance, the pivotal role of healthcare professionals in prescribing tailored solutions based on individual patient assessments cannot be overstated. Join Pharmacist Gerald Quigley as he shares his personal experience and research overview of EA575® in young children presenting with chesty cough.

Read More
our source to patient philosophy bg image

Our Source To Patient Philosophy

We make sure our natural medicines are consistent.

Not only do the clinical studies on our products demonstrate real health outcomes, they demonstrate the results you can expect from the same products you see on shelf. It’s all part of our Source to Patient philosophy.

See the steps taken to make our products

References

  1. Lang C, et al., Planta Med2015;81:968-974.
  2. Lang C, et al., Zeitschrift für Phytotherapie2015;36:192-196.
  3. Fazio S, et al., Phytomedicine2009;16.1:17-24.
  4. Schaefer A, et al., Pharmazie 2016;71(9):504-509.
  5. Bolbot Y, et al., Drugs of Ukraine 2004;11:1-4.
  6. Kraft K. Zeitschrift für Phytotherapie2004;25:179-181.
  7. Maidannik V, et al., Pediatrics, Tocology and Gynecology2003;4:1-7.
  8. Meyer-Wegener, J et al., Zeitschrift für Allgemeinmedizin1993;69:61-66.
  9. Schlenger R. Deutsche Apotheker Zeitung2003;143(49) [translation].
  10. Runkel F, et al., Pharmazeutische Zeitung2005;15.04:19-25.
  11. European Medicines Agency, Committee on Herbal Medicinal Products, EU  herbal monograph on Hedera helix. Retrieved from link.
  12. Gaedcke F. Deutsche Apotheker Zeitung1991;131:2251-2255.
  13. IMS MIDAS data, Absatz MAT12/2017.